Kearns-Sayre syndrome (KSS) is a rare multisystemic disorder, which is a condition that affects many parts of the body, especially the eyes. Kearns-Sayre syndrome belongs to a group of rare disorders known as mitochondrial myopathies. Mitochondrial myopathies are a group of neuromuscular disorders that are caused by mitochondrial dysfunction. Mitochondria is commonly known as the powerhouse of the cell, which is a small energy-producing structure. The nerve cells which reside in the brain require a lot of energy and hence they appear to be damaged when mitochondrial dysfunction occurs. Kearns-Sayre syndrome symptoms usually occur before the age of 20, and the disorder is identified by a few characteristic signs and symptoms. Moreover, external ophthalmoplegia (weakness or paralysis of the eye muscles) impairs eye movement and causes drooping eyelids (ptosis) in people with Kearns-Sayre syndrome. The symptoms observed are blindness, weakness in muscle cells, heart failure, vomiting, deafness, and seizures. The prognosis of the disorders in severity ranges from progressive weakness to death.
COVID-19 Impact Analysis
- COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global Kearns-Sayre syndrome market.
Top Impacting Factors
Increasing number of cases of mitochondrial myopathies across the globe helps to boost the growth of market. Rising number of screening for genetic diseases, increasing geriatric population, ongoing clinical trials uplift the market growth.
In addition, rise in investment by R&D in pharmaceutical companies and increase in the availability of healthcare policies are some of the crucial factors driving the Kearns-Sayre syndrome market growth.
Furthermore, rise in research and development activities to develop novel therapies, increase in healthcare expenditure, and improving healthcare infrastructure positively impact the market growth.
However, poor number of treatment options due to rare nature of the disease and unavailability of curative treatment restrain the growth of the market.
Market Trends
New Product Launches to Flourish the Market
- In October 2019, Alexion Pharmaceuticals, Inc. and Stealth BioTherapeutics Corp. announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. It is evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM)—a genetic mitochondrial disease. The elamipretide is a novel, potential therapy that targets mitochondrial dysfunction.
- In January 2020, NeuroVive Pharmaceutical AB recruited a few healthy candidates for the second installment of Phase 1a/b study, focused on testing KL1333, its oral treatment candidate for mitochondrial diseases. The study is performed to develop an investigational molecule that could help treat various genetic mitochondrial diseases, such as mitochondrial encephalomyopathy and Kearns-Sayre syndrome.
Key Benefits of the Report
- This study presents the analytical depiction of the Kearns-Sayre syndrome market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Kearns-Sayre Syndrome Market Report
- Which are the leading market players active in the Kearns-Sayre syndrome market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is Kearns-Sayre syndrome market?
- What is Kearns-Sayre syndrome market prediction in the future?
- Who are the leading global players in the Kearns-Sayre syndrome market?
- What are the current trends and predicted trends?
- What are the key benefits of the Kearns-Sayre syndrome market report?
Key Market Segments
- By Test Type
- Genetic Test
- Muscle Biopsy
- Biochemical Test
- By Drug Type
- CoQ10
- L-carnitine
- Creatine
- By Treatment Type
- Vitamins
- Anti-oxidants
- Supportive & Targeted Therapy
- By Route of Administration
- Oral
- Injection
- Intravenous
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Gino Cortopassi
- Abliva AB.
- Stealth Bio Therapeutics Inc.
- CENTOGENE N.V.
- Reata Pharmaceuticals Inc.
- GeneDx Inc
- Mitobridge Inc.
- AbbVie Inc
- Khondrion BV